Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-08-11

Clinical Trial Update: A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment [Phase 4]

View source ↗

Summary

Phase 4 study evaluating peginterferon alfa-2a (Pegasys) in combination with ribavirin (Copegus) for chronic hepatitis C across varying degrees of renal impairm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Copegus (ribavirin)
  • Pegasys (pegylated interferon alfa-2a)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Hepatitis C, Chronic | Phase 4 | Status: COMPLETED